Chordia Therapeutics,Inc Logo

Chordia Therapeutics,Inc

Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.

190A | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
藤沢市村岡東2−26−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class anti-cancer drugs. Established in November 2017 as a spin-out from a major pharmaceutical company, its mission is to deliver novel treatments to patients with unmet medical needs. The company focuses on developing a pipeline of small-molecule drug candidates that target RNA deregulation stress, a key factor in cancer development. Chordia Therapeutics operates with a focused R&D model, outsourcing activities such as manufacturing, distribution, and sales to external partners to advance its therapeutic programs.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Chordia Therapeutics,Inc and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-05 08:30
Prospectus
有価証券届出書(参照方式)
Japanese 534.8 KB
2025-05-16 02:45
Regulatory News Service
臨時報告書
Japanese 20.2 KB
2025-04-11 04:50
Interim Report
半期報告書-第8期(2024/09/01-2025/08/31)
Japanese 144.4 KB
2025-04-11 04:50
Regulatory News Service
確認書
Japanese 8.1 KB
2024-12-17 07:30
Regulatory News Service
訂正確認書
Japanese 8.7 KB
2024-11-29 07:37
Regulatory News Service
臨時報告書
Japanese 23.1 KB
2024-11-29 07:36
Regulatory News Service
確認書
Japanese 8.1 KB
2024-11-29 07:35
Regulatory News Service
内部統制報告書-第7期(2023/09/01-2024/08/31)
Japanese 21.2 KB
2024-11-29 07:34
Annual Report
有価証券報告書-第7期(2023/09/01-2024/08/31)
Japanese 2.8 MB
2024-07-16 06:55
Quarterly Report
四半期報告書-第7期第3四半期(2024/03/01-2024/05/31)
Japanese 123.4 KB
2024-07-16 06:55
Regulatory News Service
確認書
Japanese 8.0 KB
2024-06-06 08:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-29 04:00
Regulatory News Service
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-10 08:00
Prospectus
有価証券届出書(新規公開時)
Japanese 5.7 MB

Automate Your Workflow. Get a real-time feed of all Chordia Therapeutics,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Chordia Therapeutics,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan 9227
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan 3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan 4883
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden MODTX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland MOC
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A

Talk to a Data Expert

Have a question? We'll get back to you promptly.